Respiratory syncytial virus mRNA vaccine
AssigneeVernagen, LLC
InventorsBaek Kim, Jack Yoon, David Pak
Life of this patent
Estimating the term…
Loading patent…
AssigneeVernagen, LLC
InventorsBaek Kim, Jack Yoon, David Pak
Estimating the term…
Provided herein are a respiratory syncytial virus (RSV) vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding RSV mutant F B strain protein, and optionally a mRNA including an ORF encoding RSV mutant F A strain protein, and a method of inducing immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Provided herein are also a respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition including a mRNA including an ORF encoding RSV mutant F A strain protein, a mRNA including an ORF encoding RSV mutant F B strain protein, and a mRNA including an ORF encoding hMPV F protein, and a method of inducing immune response against RSV and hMPV by administering an effective amount of the RSV and hMPV vaccine composition to a subject in need thereof.
A respiratory syncytial virus (RSV) vaccine composition comprising
A respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition comprising
Dependencies are inferred from the claim text.